TTY Biopharm (Taiwan) Performance
| 4105 Stock | TWD 73.80 1.10 1.51% |
The entity has a beta of 0.17, which indicates not very significant fluctuations relative to the market. As returns on the market increase, TTY Biopharm's returns are expected to increase less than the market. However, during the bear market, the loss of holding TTY Biopharm is expected to be smaller as well. At this point, TTY Biopharm has a negative expected return of -0.0157%. Please make sure to validate TTY Biopharm's potential upside, kurtosis, and the relationship between the value at risk and skewness , to decide if TTY Biopharm performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days TTY Biopharm Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, TTY Biopharm is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 2.2 B | |
| Total Cashflows From Investing Activities | -168.8 M |
TTY |
TTY Biopharm Relative Risk vs. Return Landscape
If you would invest 7,460 in TTY Biopharm Co on August 26, 2024 and sell it today you would lose (80.00) from holding TTY Biopharm Co or give up 1.07% of portfolio value over 90 days. TTY Biopharm Co is generating negative expected returns and assumes 0.4717% volatility on return distribution over the 90 days horizon. Simply put, 4% of stocks are less volatile than TTY, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
TTY Biopharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TTY Biopharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TTY Biopharm Co, and traders can use it to determine the average amount a TTY Biopharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0334
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4105 |
Estimated Market Risk
| 0.47 actual daily | 4 96% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average TTY Biopharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TTY Biopharm by adding TTY Biopharm to a well-diversified portfolio.
TTY Biopharm Fundamentals Growth
TTY Stock prices reflect investors' perceptions of the future prospects and financial health of TTY Biopharm, and TTY Biopharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TTY Stock performance.
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0824 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 20.05 B | |||
| Shares Outstanding | 248.65 M | |||
| Price To Earning | 13.04 X | |||
| Price To Book | 3.78 X | |||
| Price To Sales | 4.10 X | |||
| Revenue | 4.54 B | |||
| EBITDA | 1.27 B | |||
| Cash And Equivalents | 2.89 B | |||
| Cash Per Share | 11.63 X | |||
| Total Debt | 4.15 M | |||
| Debt To Equity | 19.30 % | |||
| Book Value Per Share | 21.97 X | |||
| Cash Flow From Operations | 1.26 B | |||
| Earnings Per Share | 4.79 X | |||
| Total Asset | 9.3 B | |||
About TTY Biopharm Performance
Evaluating TTY Biopharm's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TTY Biopharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TTY Biopharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
TTY Biopharm Company Limited, together with its subsidiaries, produces various pharmaceuticals and chemical drugs in Taiwan and internationally. The company was founded in 1960 and is headquartered in Taipei City, Taiwan. TTY BIOPHARM is traded on Taiwan OTC Exchange in Taiwan.Things to note about TTY Biopharm performance evaluation
Checking the ongoing alerts about TTY Biopharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TTY Biopharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TTY Biopharm generated a negative expected return over the last 90 days | |
| About 21.0% of the company shares are owned by insiders or employees |
- Analyzing TTY Biopharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TTY Biopharm's stock is overvalued or undervalued compared to its peers.
- Examining TTY Biopharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TTY Biopharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of TTY Biopharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TTY Biopharm's stock. These opinions can provide insight into TTY Biopharm's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TTY Stock Analysis
When running TTY Biopharm's price analysis, check to measure TTY Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TTY Biopharm is operating at the current time. Most of TTY Biopharm's value examination focuses on studying past and present price action to predict the probability of TTY Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TTY Biopharm's price. Additionally, you may evaluate how the addition of TTY Biopharm to your portfolios can decrease your overall portfolio volatility.